b) C_{1-4} alkyl, which alkyl is unsubstituted or substituted with one or more independently selected halo, -OH, -CN, C_{1-4} alkoxy, or C_{3-7} cycloalkyl, which cycloalkyl is unsubstituted or substituted with one or more independently selected halo,

c) C_{3-6} cycloalkyl which cycloalkyl is unsubstituted or substituted with one or more independently selected oxo, -OH, -CN, C_{1-4} alkyl, C_{1-4} alkoxy, or halo, or

d) 4-6 membered heterocycloalkyl comprising one or two independently selected N, S, or O atoms, which heterocycloalkyl is unsubstituted or substituted with one or more independently selected oxo, -OH, -CN, C_{1-4} alkyl, C_{1-4} alkoxy, or halo; or

R^{3a} and R^{3b} together with the N atom to which they are attached form a 4-6 membered monocyclic heterocycloalkyl;

each R^4 is independently

a) oxo,

b) -OH,

c) -CN,

d) halo,

e) C_{1-4} alkyl unsubstituted or substituted with one or independently selected more halo, -OH, or -CN,

f) C_{1-4} alkoxy unsubstituted or substituted with one or more independently selected halo, -OH, or -CN, or

g) C_{3-7} cycloalkyl unsubstituted or substituted with one or more independently selected halo, -OH or -CN; and

R^5 is selected from H, halo, $-CH_3$ or $-CF_3$;


or a pharmaceutically acceptable salt thereof, or a solvate or the salt of the solvate thereof~~, or a metabolite thereof~~.

[0012b] In another aspect, the present disclosure refers to a pharmaceutical composition comprising a compound as disclosed herein, and a pharmaceutically acceptable carrier thereof.

[0012c] In another aspect, the present disclosure refers to a compound or pharmaceutically acceptable salt as disclosed herein, or a pharmaceutical composition as disclosed herein, for use in medicine.

[0012d] In another aspect, the present disclosure refers to a use of the compound or pharmaceutically acceptable salt as disclosed herein, or a pharmaceutical composition as disclosed herein, in the manufacture of a medicament for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases.

[0013] Accordingly, in a first example of the disclosure, the compounds of the disclosure are provided having a Formula I:




I

wherein

CLAIMS

1. A compound according to Formula I:



I

wherein

R^1 is

a) C_{2-6} alkyl substituted with one or more independently selected -OH, -CN, C_{1-4} alkoxy, halo, or -$S(=O)_2$-C_{1-4} alkyl, or

b) 6 membered heterocycloalkyl comprising one or two independently selected S, N, or O atoms, which heterocycloalkyl is unsubstituted or substituted with one or more independently selected oxo, halo, or C_{1-4} alkyl, which alkyl is unsubstituted or substituted with one or more halo;

R^2 is

a) C_{1-4} alkoxy which alkoxy is unsubstituted or substituted with one or more independently selected halo or -OH,

b) -O-C_{3-4} cycloalkyl, which cycloalkyl is unsubstituted or substituted with one or more independently selected halo or -OH, or

c) $-C(=O)NR^{3a}R^{3b}$;

Cy is 6 membered heteroaryl, comprising 1 or 2 N atoms, substituted with one or two independently selected R^4 substituents;

each R^{3a} and R^{3b} is independently selected from

a) H,

b) C_{1-4} alkyl, which alkyl is unsubstituted or substituted with one or more independently selected halo, -OH, -CN, C_{1-4} alkoxy, or C_{3-7} cycloalkyl, which cycloalkyl is unsubstituted or substituted with one or more independently selected halo,

c) C_{3-6} cycloalkyl which cycloalkyl is unsubstituted or substituted with one or more independently selected oxo, -OH, -CN, C_{1-4} alkyl, C_{1-4} alkoxy, or halo, or

d) 4-6 membered heterocycloalkyl comprising one or two independently selected N, S, or O atoms, which heterocycloalkyl is unsubstituted or substituted with one or more independently selected oxo, -OH, -CN, C_{1-4} alkyl, C_{1-4} alkoxy, or halo; or

R^{3a} and R^{3b} together with the N atom to which they are attached form a 4-6 membered monocyclic heterocycloalkyl;

each R^4 is independently

a) oxo,

b) -OH,

c) -CN,

d) halo,

e) C_{1-4} alkyl unsubstituted or substituted with one or independently selected more halo, -OH, or -CN,

f) C_{1-4} alkoxy unsubstituted or substituted with one or more independently selected halo, -OH, or -CN, or

g) C_{3-7} cycloalkyl unsubstituted or substituted with one or more independently selected halo, -OH or -CN; and


R^5 is selected from H, halo, $-CH_3$ or $-CF_3$;

or a pharmaceutically acceptable salt thereof, or a solvate or the salt of the solvate thereof~~, or a metabolite thereof~~.


2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R^1 is C_{2-6} alkyl substituted with one or more independently selected -OH, -CN, $-OCH_3$, F, Cl, or $-S(=O)_2CH_3$.

3. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R^1 is tetrahydropyranyl, dioxanyl, morpholinyl, piperidinyl, piperazinyl, thiomorpholinyl, or 1,4-oxathianyl.

4. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is according to Formula IIa or IIb:



IIa,



IIb


5. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-4, wherein R^2 is $-OCH_3$, or $-OCH_2CH_3$, each of which is unsubstituted or substituted with one or more independently selected halo or -OH.

6. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-4, wherein R^2 is $-C(=O)NR^{3a}R^{3b}$.


7. The compound or pharmaceutically acceptable salt thereof according to claim 6, wherein R^{3a} is H, $-CH_3$, $-CH_2-CH_3$, or $-CH(CH_3)_2$.

8. The compound or pharmaceutically acceptable salt thereof according to claim 6 or 7, wherein R^{3b} is H, $-CH_3$, $-CH_2-CH_3$, or $-CH(CH_3)_2$.


9. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is according to Formula IIIa, IIIb, IIIc, IVa, IVb, or IVc:




IIIa,



IIIb,



IIIc,



Iva, IVb, IVc.

10. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-9, wherein Cy is pyridinyl, or pyrazinyl, each of which is substituted with one or two independently selected R^4 substituents.

11. The compound or pharmaceutically acceptable salt thereof according to claim 10, wherein each R^4 is independently selected from oxo, -OH, -CN, F, Cl, $-CH_3$, $-CH_2-CH_3$, $-CH(CH_3)_2$, $-CF_3$, $-CHF_3$, $-CH_2CF_3$, $-CH_2CN$, $-CH_2OH$, $-CH_2CH_2-CN$, $-O-CH_2-CH_3$, cyclopropyl, cyclobutyl, cyclopropyl substituted with one or two independently selected F, or -CN, cyclobutyl substituted with one or two independently selected -F, -OH, or -CN.

12. A pharmaceutical composition comprising a compound according to any one of claims 1-11, and a pharmaceutically acceptable carrier thereof.

13. The pharmaceutical composition according to claim 12, further comprising a further therapeutic agent.

14. A compound or pharmaceutically acceptable salt according to claims 1-11, or a pharmaceutical composition according to claim 12 or 13, for use in medicine.

15. Use of the compound or pharmaceutically acceptable salt according to claims 1-11, or a pharmaceutical composition according to claim 12 or 13, in the manufacture of a medicament for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases.